Receptor Tyrosine Kinase EphB3: a Prognostic Indicator in Colorectal Carcinoma
- 51 Downloads
Although EphB3 expression is down-regulated in colorectal cancer (CRC) cells compared with normal intestinal epithelial cells, the relationship between EphB3 expression and clinicopathological parameters in CRC is unclear. We examined EphB3 expression in 128 CRC tissue specimens and in 19 adenoma specimens using immunohistochemistry. The relationships between EphB3 expression and clinicopathological parameters, KRAS mutations, BRAF V600E mutation, MSI and survival were evaluated using Spearman’s rank correlation and Kaplan–Meier survival analyses, respectively. CpG methylation in the EphB3 promoter was examined in four human CRC cell lines and tissues. EphB3 was strongly expressed in all normal intestinal epithelial cells (128/128) and adenoma cells (19/19). In CRC tumor cells, EphB3 expression was negative or weak in 41.4% (53/128), moderate in 26.6% (34/128), and strong in 32.0% (41/128) of samples. EphB3 expression was negatively associated with invasive depth (P = 0.016, rs = −0.213), lymph node metastasis (P = 0.000, rs = −0.490), and TNM stage (P = 0.000, rs = −0.390), and was positively associated with poor differentiation (P = 0.001, rs = 0.290), BRAF V600E mutation (P = 0.008, rs = 0.235), and longer overall survival (P < 0.001). In multivariate analysis, EphB3 expression (P = 0.007) and lymph node metastasis (P < 0.001) were independent prognostic factors for poor survival. Hypermethylation of the EphB3 promoter was detected in cell lines and CRC tissues. EphB3 is down-regulated in CRC compared to normal mucosa. Hypermethylation of CpG island is contributed to downregulation of EphB3 in CRC. EphB3 expression in tumor cells may be a useful prognostic indicator for patients with CRC.
KeywordsColorectal cancer EphB3 Hypermethylation Lymph node metastasis TNM stage
The authors wish to thank the patients who participate in this study. This study was supported by grants from the National Basic Research Priorities Program 973 Project (2014CB744504) from the Ministry of Science and Technology of China and the National Natural Science Foundation of China (81371611).
We thank Anne M. O’Rourke, PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.
Compliance with Ethical Standards
Conflicts of Interest
The authors declare no conflicts of interest.
- 1.(1997) Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell 90(3):403–404Google Scholar
- 6.Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L (2003) High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163(6):2271–2276. https://doi.org/10.1016/S0002-9440(10)63584-5 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10(15):5145–5150. https://doi.org/10.1158/1078-0432.CCR-03-0589
- 8.Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, Maruyama K, Isogaki J, Kanaoka S, Ihara M, Tanaka M, Kanamori M, Nakamura T, Shinmura K, Sugimura H (2005) Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24(36):5637–5647. https://doi.org/10.1038/sj.onc.1208720 CrossRefPubMedGoogle Scholar
- 10.Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick A, Himanen JP, Chaganti RS, Wendel HG (2011) The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147(3):554–564. https://doi.org/10.1016/j.cell.2011.09.035 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, Storkus WJ (2005) Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11(1):226–231Google Scholar
- 14.Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM (2009) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15(13):4423–4430. https://doi.org/10.1158/1078-0432.CCR-09-0473
- 16.Bai YQ, Zhang JY, Bai CY, Xu XE, Wu JY, Chen B, Wu ZY, Wang SH, Shen J, Shen JH, Yao XD, Gao LZ, Wu B, Gu HL, Liu XH, Li X, Li EM, Xu LY (2015) Low EphA7 expression correlated with lymph node metastasis and poor prognosis of patients with esophageal squamous cell carcinoma. Acta Histochem Cytochem 48(3):75–81. https://doi.org/10.1267/ahc.14054 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Dawson DW, Hong JS, Shen RR, French SW, Troke JJ, Wu YZ, Chen SS, Gui D, Regelson M, Marahrens Y, Morse HC 3rd, Said J, Plass C, Teitell MA (2007) Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 26(29):4243–4252. https://doi.org/10.1038/sj.onc.1210211 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Ji XD, Li G, Feng YX, Zhao JS, Li JJ, Sun ZJ, Shi S, Deng YZ, Xu JF, Zhu YQ, Koeffler HP, Tong XJ, Xie D (2011) EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 71(3):1156–1166. https://doi.org/10.1158/0008-5472.CAN-10-0717 CrossRefPubMedGoogle Scholar
- 24.Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, Clevers H (2002) Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111(2):251–263CrossRefPubMedGoogle Scholar
- 25.Jagle S, Ronsch K, Timme S, Andrlova H, Bertrand M, Jager M, Proske A, Schrempp M, Yousaf A, Michoel T, Zeiser R, Werner M, Lassmann S, Hecht A (2014) Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through decommissioning of a transcriptional enhancer. Proc Natl Acad Sci U S A 111(13):4886–4891. https://doi.org/10.1073/pnas.1314523111 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435(7045):1126–1130. https://doi.org/10.1038/nature03626 CrossRefPubMedGoogle Scholar